Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Shanghai Jiao Tong University of Medicine |
---|---|
Information provided by: | Shanghai Jiao Tong University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00713557 |
SRACE is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. SRACE includes over 20 hospitals in Shanghai China that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. The major purpose of the SRACE program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. All participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.
Condition | Intervention |
---|---|
Coronary Artery Disease Acute Coronary Syndrome |
Device: drug-eluting stent |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Phase 4 Study to Compare Different Therapeutic Strategies for Patients With ACS |
Estimated Enrollment: | 20000 |
Study Start Date: | March 2005 |
Groups/Cohorts | Assigned Interventions |
---|---|
1
patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention
|
Device: drug-eluting stent
drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
|
2
patients with acute ST-elevation myocardial infarction treated by thrombolysis
|
|
3
patients with non-ST-elevation ACS treated by immediate PCI
|
Device: drug-eluting stent
drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
|
4
patients with non ST-elevation ACS treated by elective PCI
|
Device: drug-eluting stent
drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
patients admitted to the hospital with acute coronary syndrome
Inclusion Criteria:
Exclusion Criteria:
Contact: Qi Zhang, MD, PhD | 86-21-64370045 ext 665301 | zhangqnh@yahoo.com |
China | |
Dept. of Cardiology, Ruijin Hospital | Recruiting |
Shanghai, China, 200025 | |
Contact: Xin Chen, MD 86-21-64370045 ext 665318 rjchenxin@yahoo.com.cn |
Principal Investigator: | Wei Feng Shen, MD,PhD | Ruijin Hospital, Shanghai Jiaotong University School of Medicine |
Responsible Party: | Ruijin Hospital, Shanghai Jiaotong University School of Medicine ( Wei Feng Shen, MD, PhD, Professor in Medicine ) |
Study ID Numbers: | RJH |
Study First Received: | July 7, 2008 |
Last Updated: | July 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00713557 |
Health Authority: | China: Ethics Committee |
coronary angioplasty |
Sirolimus Arterial Occlusive Diseases Coronary Disease Heart Diseases Paclitaxel Myocardial Ischemia |
Acute Coronary Syndrome Vascular Diseases Arteriosclerosis Ischemia Coronary Artery Disease |
Pathologic Processes Disease Syndrome Cardiovascular Diseases |